ArticleNeuro-oncology2016
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 78 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Genetic Variants Impacting Angiogenesis Signaling Pathways in Glioblastoma Multiforme: A Systematic Review of Mutations and Polymorphisms.Current molecular medicine · 2024Pooled it
- Advancing precision risk stratification in adult diffuse gliomas through DSC-MRI-based habitat analysis.BMC medical imaging · 2026Article
- Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study.The oncologist · 2026Article
- Development of a highly differentiated rat brain organoid model for exploring glioblastoma invasion dynamics and therapy.Neuro-oncology · 2026Article
- Tropism Profiling of Lentiviral Vector Pseudotypes in Diverse Brain Tumor Models.Pharmaceutics · 2026Article
- The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Journal of hematology & oncology · 2025Review
- Polymeric Nanoparticle-Mediated Photodynamic Therapy: A Synergistic Approach for Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Gasdermin E in glioblastoma -pyroptosis resistance and tumor-promoting functions.Cell death discovery · 2025Article
- Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma.Cancer immunology, immunotherapy : CII · 2025Article
- Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation.Journal for immunotherapy of cancer · 2025Article
- Integrated proteomics and N-glycoproteomic characterization of glioblastoma multiform revealed N-glycosylation heterogeneities as well as alterations in sialyation and fucosylation.Clinical proteomics · 2025Article
- The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.International journal of molecular sciences · 2025Review
- PCBP2-dependent secretion of miRNAs via extracellular vesicles contributes to the EGFR-driven angiogenesis.Theranostics · 2025Article
- In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development.Neuro-oncology · 2024Review
- EGFR mutations and abnormal trafficking in cancers.Molecular biology reports · 2024Review
- EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.Neuro-oncology · 2024Article
- A Synopsis of Biomarkers in Glioblastoma: Past and Present.Current issues in molecular biology · 2024Review
- Deciphering the role of transcription factors in glioblastoma cancer stem cells.Acta biochimica et biophysica Sinica · 2024Review
- Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology.Trends in cancer · 2024Review
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2016
Authors and funding
31 authors at 7 institutions in 6 countries.
Eskil EskilssonDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Gro V RoslandDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Krishna M TalasilaDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Stian KnappskogDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Olivier KeunenDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Andrea SottorivaDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Sarah FoersterDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Gergely SoleckiDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Torfinn TaxtDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Radovan JirikDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Sabrina FritahDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Patrick N HarterDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Kristjan VälkDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Jubayer Al HossainDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Justin V JosephDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Roza JahediDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Halala S SaedDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Sara G PiccirilloDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Inma SpiteriDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Lina LeissDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Philipp EuskirchenDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Grazia GrazianiDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Thomas DaubonDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Morten Lund-JohansenDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Per Øyvind EngerDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Frank WinklerDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Christoph A RitterDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Simone P NiclouDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Colin WattsDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Rolf BjerkvigDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Hrvoje MileticDepartment of Biomedicine, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., T.T., K.V., J.A.H., J.V.J., R.J., H.S.S., L.L., T.D., P.Ø.E., R.B., H.M.); KG Jebsen Brain Tumor Research Center, University of Bergen, Norway (E.E., G.V.R., K.M.T., O.K., K.V., J.A.H., J.V.J., T.D., P. Ø.E., S.P.N., R.B., H.M.); Department of Clinical Science, University of Bergen, Norway (S.K.); Department of Oncology, Haukeland University Hospital, Bergen, Norway (S.K.); Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg (O.K., S.F., S.P.N., R.B.); Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK (A.S.); Department of Clinical Pharmacy, Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany (S.F., C.A.R.); Department of Neurooncology, University Hospital Heidelberg, Germany (G.S., F.W.); Institute of Scientific Instruments, ASCR, Brno, Czech Republic (R.J.); Edinger-Intsitute, Goethe-University Medical School, Frankfurt am Main, Germany (P.N.H.); Department of Pathology, Haukeland University Hospital, Bergen, Norway (J.A.H., H.M.); Department of Clinical Neurosciences, University of Cambridge, UK (S.G.P., C.W.); Statistics and Computational Biology Laboratory, University of Cambridge, UK (I.S.); Neuro Clinic, Haukeland University Hospital, Bergen, Norway; Department of Experimental Neurology, Charité - Universitätsmedizin Berlin, Germany (P.E.); Department of Systems Medicine, University of Rome «Tor Vergata», Rome, Italy (G.G.); INSERM U1029 - University of Bordeaux, Allée Geoffroy St. Hilaire, Pessac, France (T.D.); Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (M.L.-J., P. Ø.E.).
Heidelberg University · DENorwegian Womens Public Health Association · NOUniversity of Bergen · NOGoethe University Frankfurt · DEUniversity Hospital Heidelberg · DEHaukeland University Hospital · NOUniversität Greifswald · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmplification of the epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are among the most common genetic alterations in glioblastoma (GBM), the most frequent and most aggressive primary brain tumor.
methodsIn the present work, we analyzed the clonal evolution of these major EGFR aberrations in a small cohort of GBM patients using a unique surgical multisampling technique. Furthermore, we overexpressed both receptors separately and together in 2 patient-derived GBM stem cell lines (GSCs) to analyze their functions in vivo in orthotopic xenograft models.
resultsIn human GBM biopsies, we identified EGFR amplification as an early event because EGFRvIII mutations emerge from intratumoral heterogeneity later in tumor development. To investigate the biological relevance of this distinct developmental pattern, we established experimental model systems. In these models, EGFR
conclusionsThe presented work shows that sequential EGFR amplification and EGFRvIII mutations might represent concerted evolutionary events that drive the aggressive nature of GBM by promoting invasion and angiogenesis via distinct signaling pathways. In particular, c-SRC may be an attractive therapeutic target for tumors harboring EGFRvIII as we identified this protein specifically mediating angiogenic tumor growth downstream of EGFRvIII.
Indexed as
BrainBrain NeoplasmsCell Line, TumorErbB ReceptorsEvolution, MolecularGlioblastomaHumansMultimodal ImagingMutationNeoplasm InvasivenessNeovascularization, PathologicProto-Oncogene Proteins pp60(c-src)Survival AnalysisUp-RegulationEGFR protein, humanepidermal growth factor receptor VIIIErbB ReceptorsProto-Oncogene Proteins pp60(c-src)angiogenesisEGFREGFRvIIIglioblastomainvasion
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.